Thank you for your interest in this questionnaire study on the potential relationship between psychedelic experiences and reduction or cessation of addictive behaviors. This research is being conducted by scientists at Johns Hopkins University School of Medicine and has been approved by the Johns Hopkins University Institutional Review Board (IRB). Principal Investigator: Matthew Johnson, PhD. Research Study Protocol: IRB00036856

Our Previous Research Our research team has conducted surveys characterizing positive and challenging experiences after taking psychedelics in non­laboratory settings, as well as instances in which taking a psychedelic was associated with a cessation or reduction in cigarette smoking. We've also studied both positive and psychologically difficult experiences, as well as headaches, after giving psilocybin to volunteers in our laboratory.

Purpose of This Study The goal of this survey is to learn more about whether use of psychedelic drugs may be associated with reduction or cessation of addictive behaviors. We want to characterize people's experiences in non-laboratory settings in which taking a psychedelic may have led to reducing or quitting alcohol or another drug. For the purposes of this survey, we will be asking specifically about individuals who have quit or reduced using alcohol, opioids (heroin, morphine, hydrocodone, oxycodone, codeine, Oxycontin, Vicodin, Percocet, etc.), stimulants (cocaine, methamphetamine, amphetamine, methylphenidate, Adderall, Ritalin, Dexedrine, etc.), or cannabis after a psychedelic experience. For example, if you had an alcohol abuse problem that improved after a psychedelic experience, you would be a good candidate for this study. For the purposes of this survey, a psychedelic experience can refer to an experience with psilocybin (magic) mushrooms, LSD, morning glory seeds, mescaline, peyote cactus, San Pedro cactus, DMT, Ayahuasca, or MDMA (ecstasy). ...[Continue reading on Surveymonkey]